Table 1 Population characteristics and comparison between symptomatic and non-symptomatic aortitis patients
From: Symptomatic aortitis at giant cell arteritis diagnosis: a prognostic factor of aortic event
Total n = 171 | noS-Ao n = 116 | S-Ao n = 55 | P | |
|---|---|---|---|---|
Characteristics at GCA diagnosis | ||||
Gender (Female) n (%) | 127 (74%) | 91 (78%) | 36 (65%) | 0.1 |
Mean age at GCA diagnosis (years) ± SD | 70 ± 9.0 | 70.6 ± 8.8 | 68.6 ± 9.5 | 0.19 |
Headache n (%) | 86 (51%) | 66 (57%) | 20 (39%) | 0.05 |
Temporal pulse abnormality n (%) | 33 (21%) | 27 (25%) | 6 (13%) | 0.14 |
Positive TAB n (%) | 102 (60%) | 73 (63%) | 29 (53%) | 0.27 |
CRP at diagnosis (mg/l) ± SD | 104 ± 71.4 | 108 ± 74.6 | 68.6 ± 9.5 | 0.19 |
Mandibular impairment n (%) | 31 (19%) | 28 (25%) | 3 (6%) | < 0.01 |
Fever n (%) | 73 (43%) | 57 (49%) | 16 (3%) | 0.17 |
Ophthalmological impairment n (%) | 23 (14%) | 19 (17%) | 4 (7%) | 0.16 |
Asthenia n (%) | 139 (82%) | 100 (87%) | 39 (71%) | 0.02 |
Weight loss n (%) | 89 (53%) | 65 (57%) | 24 (44%) | 0.19 |
PMR n (%) | 37 (22%) | 27 (24%) | 10 (19%) | 0.58 |
Aortic aneurysm n (%) | 32 (19%) | 13 (11%) | 19 (35%) | < 0.001 |
Aortic dissection n (%) | 8 (5%) | 2 (2%) | 6 (11%) | 0.01 |
Aortic thickening in mm ± SD | 4 ± 1.5 | 3.6 ± 1.0 | 4.6 ± 1.8 | 0.001 |
Cardiovascular risk factors | ||||
Arterial hypertension n (%) | 75 (44%) | 44 (38%) | 31 (56%) | 0.04 |
Active or withdrawn smoking < 3 years n (%) | 38 (22%) | 20 (17%) | 18 (33%) | 0.04 |
Hypercholesterolemia n (%) | 36 (21%) | 22 (19%) | 14 (25%) | 0.46 |
Obesity (BMI > 30Kg/m2) n (%) | 20 (12%) | 11 (10%) | 9 (17%) | 0.3 |
Diabetes n (%) | 15 (9%) | 10 (9%) | 5 (9%) | > 0.99 |
Treatment | ||||
Initial prednisone dose (mg/kg/d) ± SD | 0.8 ± 0.2 | 0.9 ± 0.2 | 0.8 ± 0.3 | 0.55 |
Perfusion of methylprednisolone at diagnosis, n (%) | 28 (17%) | 24 (21%) | 4 (7%) | 0.046 |
Immunosuppressive treatment introduced at diagnosis, n (%) | 7 (4%) | 6 (5.5%) | 1 (2%) | 0.43 |
Antiplatelet introduced at diagnosis, n (%) | 107 (65%) | 75 (66%) | 32 (63%) | 0.78 |
Statin treatment introduced at diagnosis, n (%) | 36 (22%) | 28 (25%) | 8 (16%) | 0.26 |
Follow-up | ||||
Mean prednisone at 12 months (mg/d) ± SD | 7.23 ± 5.6 | 7.83 ± 6.5 | 6.12 ± 3.3 | 0.08 |
Immunosuppressive treatment introduced during follow-up, n (%) | 31 (18.1%) | 24 (20.7%) | 7 (12.7%) | 0.23 |
Aortic imaging during follow up ≥2 evaluations n (%) | 56/98 (57%) | 27/54 (50%) | 29/44 (66%) | 0,11 |
Median time between aortitis diagnosis and last aortic evaluation (months) [min-max] | 24 [1–180] | 23.5 [1–180] | 25 [4–109] | 0.77 |
Median follow-up (months) [min-max] | 38 [0–237] | 30 [0–237] | 55 [7–139] | 0.41 |